Clinical Trials Browser

OTHER × Sarcoma × Imatinib Mesylate × Clear all

NCT02413736 2025-03-12

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Phase 3 Active not recruiting

Sarcoma

NCT04138381 2023-03-27

SeliGIST

Phase 1/2 Unknown

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT00116935 2011-12-30

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Phase 3 Completed

GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors